# Phase 1 Lymphoma, Non-Hodgkin trials recruiting: 64 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 64 trials in phase 1 for Lymphoma, Non-Hodgkin that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Lymphoma, Non-Hodgkin trials: 64 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/lymphoma-non-hodgkin

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 64
- Recruiting or not yet: 64
- Read on: November 19, 2026

## Trials

The 25 newest of 64, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 23, 2026 | NCT07891468 | huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers | University of Pennsylvania | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Richter's Transformation | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891468) |
| October 20, 2026 | NCT07883941 | Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid... | Sponsor not shown (see the record) | Phase 1 | Not yet recruiting | Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies, Diffuse Large B Cell Lymphoma... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883941) |
| September 24, 2026 | NCT07838649 | Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity | Washington University School of Medicine | Phase 1 | Not yet recruiting | Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma, Hodgkin Lymphoma | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838649) |
| July 1, 2026 | NCT07679919 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | Luminary Therapeutics | Phase 1 | Not yet recruiting | Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, Multiple Myeloma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679919) |
| June 3, 2026 | NCT07623850 | A Phase I Study of JLM019 Injection | Jecho Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma, Non-Hodgkin Lymphoma | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623850) |
| June 2, 2026 | NCT07620314 | Safety and Efficacy of KSVCBD Injection in B-cell Non-Hodgkin's Lymphoma Expressing CD19 and/or BCMA | Chinese PLA General Hospital | Phase 1 | Recruiting | Non-Hodgkin's Lymphoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620314) |
| May 22, 2026 | NCT07603479 | JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell... | Jecho Biopharmaceuticals Co., Ltd. | Phase 1 | Recruiting | Malignancies, Solid Malignant Tumor, NHL (Non-Hodgkin Lymphoma), Solid Tumor Cancer | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07603479) |
| April 8, 2026 | NCT07518329 | Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia. | Arovella Therapeutics Ltd | Phase 1 | Recruiting | Non Hodgkin Lymphoma (NHL), Leukaemia | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518329) |
| March 18, 2026 | NCT07478848 | Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas | Abramson Cancer Center at Penn Medicine | Phase 1 | Recruiting | Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma... | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478848) |
| March 6, 2026 | NCT07456371 | PIC1 Injection Therapy for Relapsed/Refractory B-NHL | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Non-Hodgkin Lymphoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07456371) |
| December 29, 2025 | NCT07308132 | A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies | Janssen Research & Development, LLC | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin | 340 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07308132) |
| December 16, 2025 | NCT07284927 | Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Phase 1 | Recruiting | Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284927) |
| December 3, 2025 | NCT07260812 | KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | TCRx Therapeutics Co.Ltd | Phase 1 | Recruiting | Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260812) |
| November 28, 2025 | NCT07254793 | Prophylactic DLI-X for Leukemia Relapse After HCT | University of Arizona | Phase 1 | Recruiting | Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Acute Undifferentiated Leukemia (AUL), Myelodysplastic Syndrome... | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07254793) |
| November 12, 2025 | NCT07226843 | A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma | 460 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226843) |
| November 6, 2025 | NCT07225439 | Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin... | Sponsor not shown (see the record) | Phase 1 | Recruiting | Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07225439) |
| September 29, 2025 | NCT07195916 | A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Incyte Corporation | Phase 1 | Recruiting | Solid Tumors, Hematologic Malignancies | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07195916) |
| September 10, 2025 | NCT07166549 | Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) | University Hospital, Basel, Switzerland | Phase 1 | Not yet recruiting | B Cell Malignancies, B-cell Leukemia, B Cell Lymphoma, Bispecific Chimeric Antigen Receptor (CAR) T Cells, Relapsed or... | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07166549) |
| August 11, 2025 | NCT07114367 | NB02(POSELTINIB) Monotherapy in R/R Non-Hodgkin's Lymphoma | NOBO Medicine | Phase 1 | Recruiting | Non Hodgkin Lymphoma (NHL) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07114367) |
| August 3, 2025 | NCT07101328 | A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF\_FRontier-1 ) | Eli Lilly and Company | Phase 1 | Recruiting | Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell... | 215 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101328) |
| July 24, 2025 | NCT07082803 | TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas | Treeline Biosciences, Inc. | Phase 1 | Recruiting | Lymphoma, Lymphoma, Non Hodgkin | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07082803) |
| July 4, 2025 | NCT07052305 | NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With... | Washington University School of Medicine | Phase 1 | Recruiting | Large B-cell Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07052305) |
| June 13, 2025 | NCT07020533 | A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing... | City of Hope Medical Center | Phase 1 | Recruiting | Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020533) |
| April 6, 2025 | NCT06914037 | A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies | Tianjin Medical University Cancer Institute and Hospital | Phase 1 | Recruiting | Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma (CTCL), NHL (Non-Hodgkin Lymphoma) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06914037) |
| March 13, 2025 | NCT06875063 | GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL | The First Affiliated Hospital of Xiamen University | Phase 1 | Recruiting | Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06875063) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Baylor College of Medicine | 5 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 2 |
| Washington University School of Medicine | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| Jecho Biopharmaceuticals Co., Ltd. | 2 |
| [PersonGen BioTherapeutics (Suzhou) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/persongen-biotherapeutics-suzhou-co-ltd) | 1 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 1 |
| TCRx Therapeutics Co.Ltd | 1 |
| Medical College of Wisconsin | 1 |
| Umoja Biopharma | 1 |
| University of Colorado, Denver | 1 |
| National Cancer Institute (NCI) | 1 |
| Treeline Biosciences, Inc. | 1 |
| Arovella Therapeutics Ltd | 1 |
| Aurigene Discovery Technologies Limited | 1 |
| Marker Therapeutics, Inc. | 1 |
| AIDS Malignancy Consortium | 1 |
| Chinese PLA General Hospital | 1 |
| SIRPant Immunotherapeutics, Inc. | 1 |
| Newave Pharmaceutical Inc | 1 |
| Murdoch Childrens Research Institute | 1 |
| NOBO Medicine | 1 |
| Verismo Therapeutics | 1 |
| British Columbia Cancer Agency | 1 |
| Accutar Biotechnology Inc | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 41 |
| China | 15 |
| Australia | 11 |
| Spain | 6 |
| Italy | 5 |
| Canada | 5 |
| France | 4 |
| Denmark | 3 |
| Poland | 3 |
| Belgium | 2 |
| South Korea | 2 |
| Germany | 2 |
| Japan | 2 |
| United Kingdom | 2 |
| India | 1 |
| Turkey (Türkiye) | 1 |
| Switzerland | 1 |
| Taiwan | 1 |
| Moldova | 1 |
| Romania | 1 |
| Ukraine | 1 |
| Czechia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Home inspectors in the United States](https://specstream.ai/data/businesses/home-inspectors/united-states)
- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [Alternative medicine clinics in the United States](https://specstream.ai/data/businesses/alternative-medicine-clinics/united-states)
- [Salad bars in the United States](https://specstream.ai/data/businesses/salad-bars/united-states)
- [Masonry contractors in the United States](https://specstream.ai/data/businesses/masonry-contractors/united-states)
- [Fast food restaurants in the United States](https://specstream.ai/data/businesses/fast-food-restaurants/united-states)
